1
|
Naydenov N, Teplov A, Zirakchian MZ, Ruan S, Chu BP, Serencsits B, Iraca M, Talarico O, Miller B, Kunin H, Schwartz J, Kesner A, Furenlid LR, Dauer L, Yagi Y, Humm JL, Zanzonico P, Sofocleous CT, Kirov AS. Yttrium-90 Activity Quantification in PET/CT-Guided Biopsy Specimens from Colorectal Hepatic Metastases Immediately after Transarterial Radioembolization Using Micro-CT and Autoradiography. J Vasc Interv Radiol 2023; 34:1556-1564.e4. [PMID: 37201655 PMCID: PMC11163896 DOI: 10.1016/j.jvir.2023.05.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 04/13/2023] [Accepted: 05/08/2023] [Indexed: 05/20/2023] Open
Abstract
PURPOSE To evaluate the yttrium-90 (90Y) activity distribution in biopsy tissue samples of the treated liver to quantify the dose with higher spatial resolution than positron emission tomography (PET) for accurate investigation of correlations with microscopic biological effects and to evaluate the radiation safety of this procedure. MATERIALS AND METHODS Eighty-six core biopsy specimens were obtained from 18 colorectal liver metastases (CLMs) immediately after 90Y transarterial radioembolization (TARE) with either resin or glass microspheres using real-time 90Y PET/CT guidance in 17 patients. A high-resolution micro-computed tomography (micro-CT) scanner was used to image the microspheres in part of the specimens and allow quantification of 90Y activity directly or by calibrating autoradiography (ARG) images. The mean doses to the specimens were derived from the measured specimens' activity concentrations and from the PET/CT scan at the location of the biopsy needle tip for all cases. Staff exposures were monitored. RESULTS The mean measured 90Y activity concentration in the CLM specimens at time of infusion was 2.4 ± 4.0 MBq/mL. The biopsies revealed higher activity heterogeneity than PET. Radiation exposure to the interventional radiologists during post-TARE biopsy procedures was minimal. CONCLUSIONS Counting the microspheres and measuring the activity in biopsy specimens obtained after TARE are safe and feasible and can be used to determine the administered activity and its distribution in the treated and biopsied liver tissue with high spatial resolution. Complementing 90Y PET/CT imaging with this approach promises to yield more accurate direct correlation of histopathological changes and absorbed dose in the examined specimens.
Collapse
Affiliation(s)
- Nicola Naydenov
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Alexei Teplov
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Shutian Ruan
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Bae P Chu
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Brian Serencsits
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Marisa Iraca
- University of Rhode Island, Kingston, Rhode Island
| | - Olga Talarico
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Henry Kunin
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jazmin Schwartz
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Adam Kesner
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Larry Dauer
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Yukako Yagi
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - John L Humm
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Pat Zanzonico
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Assen S Kirov
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
| |
Collapse
|
2
|
Dzaye O, Cornelis FH, Kunin HS, Sofocleous CT. Advancements and Future Outlook of PET/CT-Guided Interventions. Tech Vasc Interv Radiol 2023; 26:100916. [PMID: 38071029 DOI: 10.1016/j.tvir.2023.100916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2023]
Abstract
Advancements in minimally invasive technology, coupled with imaging breakthroughs, have empowered the field of interventional radiology to achieve unparalleled precision in image-guided diagnosis and treatment while simultaneously reducing periprocedural morbidity. Molecular imaging, which provides valuable physiological and metabolic information alongside anatomical localization, can expand the capabilities of image-guided interventions. Among various molecular imaging techniques, positron emission tomography (PET) stands out for its superior spatial resolution and ability to acquire quantitative data. PET has emerged as a crucial tool for oncologic imaging and plays a pivotal role in both staging and the assessment of treatment responses. Typically used in combination with computed tomography (CT) (PET/CT) and occasionally with magnetic resonance imaging MRI (PET/MRI), PET as a hybrid imaging approach offers enhanced insights into disease progression and response. In recent years, PET has also found its way into image-guided interventions, especially within the rapidly expanding field of interventional oncology. This review aims to explore the current and evolving role of metabolic imaging, specifically PET, in interventional oncology. By delving into the unique advantages and applications of PET in guiding oncological interventions and assessing response, we seek to highlight the increasing significance of this modality in the realm of interventional radiology.
Collapse
Affiliation(s)
- Omar Dzaye
- Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging & Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Francois H Cornelis
- Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Henry S Kunin
- Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Constantinos T Sofocleous
- Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
| |
Collapse
|
4
|
Sarrut D, Bała M, Bardiès M, Bert J, Chauvin M, Chatzipapas K, Dupont M, Etxebeste A, M Fanchon L, Jan S, Kayal G, S Kirov A, Kowalski P, Krzemien W, Labour J, Lenz M, Loudos G, Mehadji B, Ménard L, Morel C, Papadimitroulas P, Rafecas M, Salvadori J, Seiter D, Stockhoff M, Testa E, Trigila C, Pietrzyk U, Vandenberghe S, Verdier MA, Visvikis D, Ziemons K, Zvolský M, Roncali E. Advanced Monte Carlo simulations of emission tomography imaging systems with GATE. Phys Med Biol 2021; 66:10.1088/1361-6560/abf276. [PMID: 33770774 PMCID: PMC10549966 DOI: 10.1088/1361-6560/abf276] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 03/26/2021] [Indexed: 12/13/2022]
Abstract
Built on top of the Geant4 toolkit, GATE is collaboratively developed for more than 15 years to design Monte Carlo simulations of nuclear-based imaging systems. It is, in particular, used by researchers and industrials to design, optimize, understand and create innovative emission tomography systems. In this paper, we reviewed the recent developments that have been proposed to simulate modern detectors and provide a comprehensive report on imaging systems that have been simulated and evaluated in GATE. Additionally, some methodological developments that are not specific for imaging but that can improve detector modeling and provide computation time gains, such as Variance Reduction Techniques and Artificial Intelligence integration, are described and discussed.
Collapse
Affiliation(s)
- David Sarrut
- Université de Lyon, CREATIS, CNRS UMR5220, Inserm U1294, INSA-Lyon, Université Lyon 1, Lyon, France
| | | | - Manuel Bardiès
- Cancer Research Institute of Montpellier, U1194 INSERM/ICM/Montpellier University, 208 Av des Apothicaires, F-34298 Montpellier cedex 5, France
| | - Julien Bert
- LaTIM, INSERM UMR 1101, IBRBS, Faculty of Medicine, Univ Brest, 22 avenue Camille Desmoulins, F-29238, Brest, France
| | - Maxime Chauvin
- CRCT, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France
| | | | | | - Ane Etxebeste
- Université de Lyon, CREATIS, CNRS UMR5220, Inserm U1294, INSA-Lyon, Université Lyon 1, Lyon, France
| | - Louise M Fanchon
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States of America
| | - Sébastien Jan
- Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, F-91401, Orsay, France
| | - Gunjan Kayal
- CRCT, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France
- SCK CEN, Belgian Nuclear Research Centre, Boeretang 200, Mol 2400, Belgium
| | - Assen S Kirov
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States of America
| | - Paweł Kowalski
- High Energy Physics Division, National Centre for Nuclear Research, Otwock-Świerk, Poland
| | - Wojciech Krzemien
- High Energy Physics Division, National Centre for Nuclear Research, Otwock-Świerk, Poland
| | - Joey Labour
- Université de Lyon, CREATIS, CNRS UMR5220, Inserm U1294, INSA-Lyon, Université Lyon 1, Lyon, France
| | - Mirjam Lenz
- FH Aachen University of Applied Sciences, Forschungszentrum Jülich, Jülich, Germany
- Faculty of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, Germany
| | - George Loudos
- Bioemission Technology Solutions (BIOEMTECH), Alexandras Av. 116, Athens, Greece
| | | | - Laurent Ménard
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
- Université de Paris, IJCLab, F-91405 Orsay France
| | | | | | - Magdalena Rafecas
- Institute of Medical Engineering, University of Lübeck, Lübeck, Germany
| | - Julien Salvadori
- Department of Nuclear Medicine and Nancyclotep molecular imaging platform, CHRU-Nancy, Université de Lorraine, F-54000, Nancy, France
| | - Daniel Seiter
- Department of Medical Physics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, 53705, United States of America
| | - Mariele Stockhoff
- Medical Image and Signal Processing (MEDISIP), Ghent University, Ghent, Belgium
| | - Etienne Testa
- Univ. Lyon, Univ. Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, F-69622, Villeurbanne, France
| | - Carlotta Trigila
- Department of Biomedical Engineering, University of California, Davis, CA 95616 United States of America
| | - Uwe Pietrzyk
- Faculty of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, Germany
| | | | - Marc-Antoine Verdier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, F-91405 Orsay, France
- Université de Paris, IJCLab, F-91405 Orsay France
| | - Dimitris Visvikis
- LaTIM, INSERM UMR 1101, IBRBS, Faculty of Medicine, Univ Brest, 22 avenue Camille Desmoulins, F-29238, Brest, France
| | - Karl Ziemons
- FH Aachen University of Applied Sciences, Forschungszentrum Jülich, Jülich, Germany
| | - Milan Zvolský
- Institute of Medical Engineering, University of Lübeck, Lübeck, Germany
| | - Emilie Roncali
- Department of Biomedical Engineering, University of California, Davis, CA 95616 United States of America
| |
Collapse
|
5
|
Khan S, Kim S, Yang YP, Pratx G. High-resolution radioluminescence microscopy of FDG uptake in an engineered 3D tumor-stoma model. Eur J Nucl Med Mol Imaging 2021; 48:3400-3407. [PMID: 33880604 DOI: 10.1007/s00259-021-05364-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 04/07/2021] [Indexed: 02/07/2023]
Abstract
PURPOSE The increased glucose metabolism of cancer cells is the basis for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). However, due to its coarse image resolution, PET is unable to resolve the metabolic role of cancer-associated stroma, which often influences the metabolic reprogramming of a tumor. This study investigates the use of radioluminescence microscopy for imaging FDG uptake in engineered 3D tumor models with high resolution. METHOD Multicellular tumor spheroids (A549 lung adenocarcinoma) were co-cultured with GFP-expressing human umbilical vein endothelial cells (HUVECs) within an artificial extracellular matrix to mimic a tumor and its surrounding stroma. The tumor model was constructed as a 200-μm-thin 3D layer over a transparent CdWO4 scintillator plate to allow high-resolution imaging of the cultured cells. After incubation with FDG, the radioluminescence signal was collected by a highly sensitive widefield microscope. Fluorescence microscopy was performed using the same instrument to localize endothelial and tumor cells. RESULTS Simultaneous and co-localized brightfield, fluorescence, and radioluminescence imaging provided high-resolution information on the distribution of FDG in the engineered tissue. The microvascular stromal compartment as a whole took up a large fraction of the FDG, comparable to the uptake of the tumor spheroids. In vitro gamma counting confirmed that A549 and HUVEC cells were both highly glycolytic with rapid FDG uptake kinetics. Despite the relative thickness of the tissue constructs, an average spatial resolution of 64 ± 4 μm was achieved for imaging FDG. CONCLUSION Our study demonstrates the feasibility of imaging the distribution of FDG uptake in engineered in vitro tumor models. With its high spatial resolution, the method can separately resolve tumor and stromal components. The approach could be extended to more advanced engineered cancer models but also to surgical tissue slices and tumor biopsies.
Collapse
Affiliation(s)
- Syamantak Khan
- Department of Radiation Oncology, Stanford University, Stanford, CA, 94305, USA
| | - Sungwoo Kim
- Department of Orthopedic Surgery, Stanford University, Stanford, CA, 94305, USA
| | - Yunzhi Peter Yang
- Department of Orthopedic Surgery, Stanford University, Stanford, CA, 94305, USA
| | - Guillem Pratx
- Department of Radiation Oncology, Stanford University, Stanford, CA, 94305, USA.
| |
Collapse
|
6
|
Bogoni M, Cerci JJ, Cornelis FH, Nanni C, Tabacchi E, SchÖder H, Shyn PB, Sofocleous CT, Solomon SB, Kirov AS. Practice and prospects for PET/CT guided interventions. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2021; 65:20-31. [PMID: 33494585 PMCID: PMC10446123 DOI: 10.23736/s1824-4785.21.03291-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
During the past 10 years, performing real-time molecular imaging with positron emission tomography (PET) in combination with computed tomography (CT) during interventional procedures has undergone rapid development. Keeping in mind the interest of the nuclear medicine readers, an update is provided of the current workflows using real-time PET/CT in percutaneous biopsies and tumor ablations. The clinical utility of PET/CT guided biopsies in cancer patients with lung, liver, lymphoma, and bone tumors are reviewed. Several technological developments, including the introduction of new PET tracers and robotic arms as well as opportunities provided through acquiring radioactive biopsy specimens are briefly reviewed.
Collapse
Affiliation(s)
| | | | | | - Cristina Nanni
- Unit of Nuclear Medicine, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Elena Tabacchi
- Unit of Nuclear Medicine, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Heiko SchÖder
- Unit of Nuclear Medicine, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Paul B Shyn
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Constantinos T Sofocleous
- Unit of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Stephen B Solomon
- Unit of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Assen S Kirov
- Unit of Molecular Imaging and Therapy Physics, Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA -
| |
Collapse
|
7
|
Kishore SA, Drabkin MJ, Sofocleous CT. Fluorodeoxyglucose-PET for Ablation Treatment Planning, Intraprocedural Monitoring, and Response. PET Clin 2020; 14:427-436. [PMID: 31472740 DOI: 10.1016/j.cpet.2019.06.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
PET has become an essential tool for staging and response assessment in oncologic imaging. Over the past decade it has also evolved into a tool for image-guided interventions, specifically in the rapidly growing field of interventional oncology. PET-guided biopsies have greater sensitivity and diagnostic yield for fluorodeoxyglucose-avid lesions. Real-time PET imaging can also provide valuable image guidance during therapeutic minimally invasive procedures such as ablation of PET-avid tumors. The increasing use of PET in the assessment of therapeutic response results in earlier identification of disease that is amenable to image-guided therapies.
Collapse
Affiliation(s)
- Sirish A Kishore
- Interventional Radiology Service, Memorial Sloan Kettering Cancer, 1275 York, IR Suite H118, New York City, NY 10065, USA
| | - Michael J Drabkin
- Interventional Radiology Service, Memorial Sloan Kettering Cancer, New York City, NY, USA
| | - Constantinos T Sofocleous
- Interventional Radiology Service, Memorial Sloan Kettering Cancer, 1275 York, IR Suite H118, New York City, NY 10065, USA.
| |
Collapse
|